BPC-157: Human Studies, FDA Vote, Compounding Status & Safety

Research brief

Four facts matter more than the hype

What changed on July 23, 2026?

FDA convened the Pharmacy Compounding Advisory Committee to consider BPC-157 free base and BPC-157 acetate for possible inclusion on the section 503A Bulks List. Importantly, the use FDA formally evaluated for BPC-157 at this meeting was ulcerative colitis—not the tendon, muscle, athletic-recovery, or injury-healing uses that dominate online promotion [1,2].

FDA staff's briefing concluded that the evaluation criteria weighed against placing both BPC-157 free base and BPC-157 acetate on the 503A list [2]. The advisory committee nevertheless voted narrowly in favor; contemporaneous reporting recorded an 8–6 vote with one abstention [5].

Human evidence ledger: every clinical study FDA found

FDA's 2026 briefing searched PubMed and Embase and identified five clinical studies that used BPC-157 [2]. Mapping them side by side shows why “human research exists” and “human efficacy is established” are very different statements.

FDA also found ClinicalTrials.gov registration NCT02637284, an estimated 42-person oral phase-1 study in healthy subjects, but reported that no results were posted and no associated published study was located in its December 2025 search [2,9]. A registered study is not the same thing as an available result.

The claims-to-evidence gap

BPC-157 is marketed around tendon repair, muscle healing, ligament recovery, gut repair, ulcer healing, neurologic recovery, inflammation, and athletic performance. FDA's formal July 2026 assessment, however, reviewed BPC-157 for ulcerative colitis and specifically noted that it did not identify human clinical studies supporting a tendonitis use in the material it evaluated [1,2].

A credible BPC-157 page therefore should not say “no human evidence” and stop there—but it also should not promote a handful of small human exposures as though they close the translational gap.

FDA and compounding status — checked August 15, 2026

Neither BPC-157 free base nor BPC-157 acetate is a component of an FDA-approved drug, and FDA's briefing states that neither has an applicable USP/NF drug-substance monograph [2]. Under section 503A, those facts matter because a bulk drug substance generally must satisfy the applicable statutory pathway—including appearing on the 503A Bulks List when no qualifying monograph or approved-drug-component route applies [3].

The July committee recommendation did not itself add BPC-157 to a final rule. FDA says it develops the 503A list through notice-and-comment rulemaking and is not legally bound by advisory-committee recommendations [1,3]. In our August 15, 2026 check of FDA's current compounding pages and rule materials, we did not locate a subsequent final rule adding BPC-157.

The BPC-157 identity problem most consumer pages miss

“BPC-157” is a common name, not a U.S. Adopted Name. FDA's briefing says it has encountered multiple salts and derivatives—including different active moieties—sold under the same common name. It separately evaluated BPC-157 free base and BPC-157 acetate as distinct bulk drug substances [2].

FDA warned that inconsistent naming can create a patient-safety problem if the material dispensed is not the bulk drug substance the prescriber intended. The agency also identified characterization gaps involving peptide-related impurities, aggregation, microbial quality, endotoxins, particle size, and dosage-form-specific critical quality attributes [2].

Human safety: reassuring observations are not a safety database

FDA noted that no serious adverse events appeared to have been reported in the five clinical studies it identified. That sounds reassuring until the denominator is examined: the studies were short, sample sizes were small, doses were exploratory, and safety monitoring was unclear or sparsely described in several reports [2].

FDA also identified three FAERS reports associated with injectable BPC-157 through December 4, 2025, involving injection-site symptoms, a report of shortness of breath/ER evaluation, and a pigmentation/gingival report with concurrent TB-500 exposure. FDA emphasized the reports were incomplete or confounded and cannot establish causality [2].

• Immunogenicity: FDA identifies potential immune-response risk for peptide products, particularly where aggregation or peptide-related impurities are possible [2,4].
• Product quality: API identity, purity, stability, sterility, microbial quality, and formulation are not guaranteed by the name “BPC-157” alone [2].
• Long-term exposure: the human studies located by FDA do not provide a robust long-duration safety dataset [2].
• Route extrapolation: FDA reported no human pharmacokinetic data for several routes commonly discussed online, including oral, subcutaneous, nasal, and transdermal use [2].

FDA's current safety-risk page therefore continues to say it has no or only limited safety-related information for proposed BPC-157 routes and lacks sufficient information to know whether compounded use would cause harm in humans [4].

Athletes: BPC-157 is an anti-doping problem even if regulation changes

The 2026 WADA Prohibited List is in force, and USADA identifies BPC-157 under the S0 Non-Approved Substances category [12,13]. That anti-doping status is a separate question from whether FDA eventually changes compounding policy.

This is not theoretical enforcement. In September 2025, USADA announced a triathlon sanction in a case involving possession and use of BPC-157 and TB-500 and stated that BPC-157 is prohibited at all times under the applicable anti-doping rules [14].

Athletes should verify the current status through Global DRO/USADA or the anti-doping organization governing their sport rather than assuming that a prescription, clinic sale, or future compounding change makes a substance permitted in competition.

Evidence applicability ledger

Unanswered-question ledger

A premium evidence page should make the missing data visible rather than fill them with mechanism or anecdotes:

1. Can any claimed tendon, ligament, or muscle-repair benefit be reproduced in adequately powered randomized human trials?
2. What are human pharmacokinetics and bioavailability for the oral, subcutaneous, nasal, and transdermal routes commonly marketed?
3. Are BPC-157 free base and acetate clinically interchangeable at any route or formulation?
4. What impurity, aggregation, sterility, stability, and immunogenicity specifications are necessary for reproducible human use?
5. What adverse events emerge with months or years of exposure rather than days or a few administrations?
6. Can the old ulcerative-colitis findings be reproduced in a modern full-text randomized trial with transparent outcomes and safety monitoring?
7. Why does the registered oral phase-1 study NCT02637284 still lack publicly posted results or a publication identified in FDA's review?
8. How closely do commercial gray-market products match the identity and purity of materials used in published studies?
9. Will FDA ultimately follow or reject the July 2026 advisory recommendation in a future 503A rulemaking action?

Frequently asked questions